Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Elpen Pharmaceutical Co. Inc.
ClinicalTrials.gov Identifier:
NCT01475045
First received: October 12, 2011
Last updated: November 18, 2011
Last verified: November 2011

October 12, 2011
November 18, 2011
January 2011
April 2011   (final data collection date for primary outcome measure)
Patients' satisfaction [ Time Frame: all study period (5 months) ] [ Designated as safety issue: No ]
Patients' replies to FSI-10 questionnaire valid in Greek language
Same as current
Complete list of historical versions of study NCT01475045 on ClinicalTrials.gov Archive Site
Patients devices' use [ Time Frame: all study period (5 months) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)
Multicenter, Prospective, Non Interventional Observational Study in Treatments of Asthma and Chronic Obstructive Pulmonary Disease (COPD)

The aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the FSI-10 questionnaire

Patients are requested to reply to FSI-10 questionnaire regarding their satisfaction from inhalation devices. Patients are on 3 different asthma inhalation devices with combination treatment (Turbuhaler, Diskus, Elpenhaler)

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Three subgroups of patients who are already in their inhalation treatment (devices: Discus, Elpenhaler, Turbuhaler) are asked to complete the FSI-10 questionnaire valid in Greek language. The questionnaire responses indicate their satisfaction by their treatment devices.

  • Asthma
  • Chronic Obstructive Pulmonary Disease
Not Provided
  • Turbuhaler inhaler use
  • Discus inhaler use
  • Elpenhaler inhaler use
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1160
September 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients > 18 years old, both genders who are on their inhalation treatment at least two months before study enrollment,
  • Who are able to be compliant to study procedures

Exclusion Criteria:

  • Patients < 18 years old,
  • Patients who are on their inhalation treatment less than two months before study enrollment
  • Patients who are not able to be compliant to study procedures
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
NCT01475045
20109-HAL-EL-02, Sponsor ID
No
Elpen Pharmaceutical Co. Inc.
Elpen Pharmaceutical Co. Inc.
Not Provided
Principal Investigator: Asimina Gaga 7th Pulmonary Clinic, Sotiria Hospital of Athens
Elpen Pharmaceutical Co. Inc.
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP